

C-Path Q1 2025 Newsletter

Hello to our C-Path Community,



As we step into this pivotal year, I'm honored to welcome you to this special edition of our C-Path newsletter—one that marks an outstanding milestone: our 20th anniversary.

Over the past two decades, C-Path has remained steadfast in its mission to accelerate the development of therapies for those who need them most. While the drug development landscape continues to evolve—with new challenges and uncertainties emerging—we embrace these complexities with determination, collaboration, and an unwavering commitment to innovation.

In this issue, we reflect on key moments that have shaped our journey and look ahead to the exciting opportunities before us, including our upcoming **C-Path Global Impact Conference**. This event will bring together thought leaders across regulatory science, industry,

patient advocacy, and academia, fostering the critical conversations and partnerships that drive progress.

Thank you for being an essential part of our story. Your support, expertise, and collaboration make our work possible. Together, we will continue to push boundaries, navigate challenges, and advance solutions that transform lives.

Here's the next chapter of innovation, partnership, and impact!

Sincerely,

A handwritten signature in black ink that reads "Klaus Romero".

Klaus Romero MD, MS, FCP
CEO


NEW! The Critical Path Institute Podcast

We hope you enjoy these engaging discussions that truly highlight C-Path's collaborative approach to advancing drug development and improving global health outcomes. Subscribe today!

Hosted by C-Path CEO Dr. Klaus Romero, the inaugural episode features guest Dr. Cheryl Coon, Vice President of C-Path's Critical Outcome Assessment (COA) Program, who explores how COAs are essential in measuring patient experiences and determining drug efficacy.

Episode 1: [Connecting the Dots with COA VP Dr. Cheryl Coon](#)

Listen and subscribe here:



Impact

Our impact stories offer a powerful glimpse into the lives of those whose journeys deeply influence our work at C-Path. These stories highlight the real-world impact of drug development showcasing how we invite those with lived experience to the table. Whether you are an individual or a family living with a given condition, an advocate, or partner, these stories will inspire and reinforce the importance of what C-Path does.



Read our latest Impact story, [Strength in Service: A Young Mother's Battle with ALS](#). Melissa Diaz-Viera recalls her diagnosis with amyotrophic lateral sclerosis (ALS) and the importance of collaboration with neutral conveners like C-Path. Through collaboration, sharing of data and resources, and the work of C-Path's Critical Path for Rare Neurodegenerative Diseases, Melissa sees a world for people living with ALS where better, more effective medicines can be tested faster, and individuals affected can feel more confident to participate in clinical trials.

"Collaboration is everything, whether you're a person with ALS trying to get through this, or you're a scientist trying to figure it out. I think the more people that we can bring together, the better, and the work that C-Path is doing is working towards that."

For our most recent [impact stories](#) and [blogs visit here](#).

LATEST NEWS


In recent news, C-Path is excited to announce the addition of two new members of our leadership team who will play pivotal roles in guiding our company's growth, impact, and vision.



[Jennifer Kendra](#) joins us as our new Vice President of Strategic Partnerships. Jenn brings a robust career spanning over two decades in strategic planning, partnership development, and executive leadership, and is uniquely positioned to guide C-Path in its work to broaden collaborative initiatives, maximize resources, and further execute the Institute's mission. Her proven expertise in exceeding organizational goals and fostering enduring partnerships will play a critical role in the expansion of C-Path's leadership in drug development.

[Paul E. Edmeier](#) joins us as our new

Chief Financial Officer. Paul brings a comprehensive background in financial management and strategic planning from both the nonprofit and private sectors to C-Path. In his new role, Edmeier will be instrumental in overseeing C-Path's financial operations globally. He is responsible for leading strategic financial initiatives, ensuring compliance with critical financial regulations, and enhancing the organization's capacity for broad-scale collaborative projects.



Earlier this year, [C-Path welcomed two new members to its Board of Directors](#): **Steven W. Spector**, an accomplished

executive who has led a wide range of corporate functions spanning legal, business development, compliance, and government relations; and **James King**, a seasoned leader

with more than 30 years of executive experience across the technology, media, and publishing sectors. Their diverse backgrounds and strategic insight bring tremendous value to C-Path's mission and will help propel our impact forward.

In February, members of C-Path's local leadership gathered in Tucson, Arizona, to commemorate our 20th anniversary. Distinguished C-Path team members delivered powerful presentations on the urgent need to accelerate drug development for the benefit of patients and global healthcare. Among them was **Hailey Davenport**, a project manager at C-Path who has lived with type 1 diabetes for 16 years. She shared her personal journey and reflected on the tangible progress made in both treatment and disease understanding—underscoring the importance of our continued work to drive innovation forward.

Watch the recap video now:



Finally, in honor of **Parkinsons Awareness Month**, C-Path's Diane Stephenson appeared on Xtalks' Life Science Podcast to discuss how digital health technologies can be vital in diagnosing and managing complex diseases like Parkinson's and Alzheimer's more effectively.



The conversation highlights how these organizations work together to create resources that allow for better utilization of digital health technologies as part of trials for novel drugs for these diseases, aiming for improved patient outcomes. Key issues addressed include opportunities for the adoption of these technologies, how they can help drug development in the important aim of early intervention, and the potential for improved patient empowerment through technology. Both speakers emphasize the need for public-private partnerships and collaborative efforts across various stakeholders to overcome challenges facing Alzheimer's and Parkinson's research.

You can watch the episode on Xtalks' YouTube page, or on the Xtalks blog [here](#).

For more C-Path press releases and additional media, [click here](#).

2025 Global Impact Conference, September 9-11, Washington, D.C.

Save the date for our Annual C-Path Global Impact Conference. Engage with colleagues and advocates from diverse sectors, including industry, regulatory agencies, academia, patient organizations, and our vibrant community of those with living experiences. This year's conference promises a dynamic agenda, bringing together a multitude of voices and perspectives to foster collaboration and open dialogue.



Keep an eye out for upcoming emails; registration opens April 18, 2025.

And be sure to contact us at the rest of our upcoming events:

- Connect with Sorin Fedeles and Wendy Ruyle (PKDOC): NKF Spring Clinical Meetings, April 9-13.
- [Register Now](#) | RDCA-DAP, April 17 Webinar: ACE Inhibitors as a Cardioprotective Treatment in Dystrophinopathies.
- Save the Date | June 17-18, T1D C-peptide Virtual Workshop
- Connect with Diane Stephenson (CPP & Neuro Program): The Michael J. Fox Foundation Annual PPMI Meeting, April 28- May 1.
- Connect with C-Path Staff: DIA 2025 Global Annual Meeting, June 15-19, Booth #1039
- Connect with Maaïke Everts (TRxA), Jennifer Kendra and Kristen Swingle: BIO International Convention, June 16-19.